Renee Bassaly, DO
Urogynecology and Reconstructive Pelvic Surgery · Tampa, FLNPI 1235399130
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.0%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Medtronic at 26.7% of the total.
Across 140 payments — averaging $67.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- C. R. Bard, Inc. & Subsidiaries$2K
- Laborie Medical Technologies Corp.$1K
- Intuitive Surgical$786
- Boston Scientific$638
- Astellas Pharma US Inc$544
- plus $2K from 21 others
Across 1 payment — averaging $532.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$533
What the payments were for
- Consulting fees$2,94031%
- Speaking & faculty fees$1,04011%
- Travel & lodging$4655%
- Food & beverage$4,74750%
- Education$3003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 23 | $2,536 |
| C. R. Bard, Inc. & Subsidiaries | 3 | $1,680 |
| Laborie Medical Technologies Corp. | 2 | $1,063 |
| Intuitive Surgical | 5 | $786 |
| Boston Scientific | 12 | $638 |
| Astellas Pharma US Inc | 17 | $544 |
| Axonics, Inc. | 19 | $477 |
| Coloplast | 6 | $232 |
| Conmed Corporation | 4 | $187 |
| Baxter Healthcare | 5 | $166 |
| Caldera Medical, Inc | 3 | $131 |
| Sumitomo Pharma America, Inc. | 5 | $126 |
| Hologic Sales And Service, LLC | 2 | $124 |
| Urovant Sciences Inc | 6 | $117 |
| TELA Bio, Inc. | 2 | $106 |
| Hollister Incorporated | 4 | $105 |
| AbbVie(2 entities) | 5 | $102 |
| Mimedx Group, Inc. | 4 | $77 |
| Femselect Inc. | 1 | $69 |
| Millicent US Inc | 3 | $62 |
| Coopersurgical, Inc. | 3 | $54 |
| Renovia Inc | 1 | $24 |
| Pfizer | 1 | $22 |
| Escala Medical Inc. | 1 | $18 |
| Davol Inc. | 1 | $18 |
| Dentsply IH AB | 1 | $15 |
| Stability Biologics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,492 in reported general payments places this provider in the 70th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.
See all urogynecology and reconstructive pelvic surgery providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 148 | $110,889 |
| GemtesaVibegron | 90 | $85,901 |
| Estradiol | 214 | $12,115 |
| Methenamine Hippurate | 91 | $11,260 |
| PremarinEstrogens, Conjugated | 23 | $10,235 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 127 | $1,339 |
| Cefdinir | 47 | $638 |
| Solifenacin Succinate | 16 | $580 |
| NitrofurantoinNitrofurantoin Macrocrystal | 12 | $450 |
| Clobetasol Propionate | 17 | $351 |
| Metronidazole | 17 | $346 |
| Oxybutynin Chloride ErOxybutynin Chloride | 16 | $241 |
| Fluconazole | 45 | $234 |
| Nystatin-TriamcinoloneNystatin/Triamcinolone Acet | 11 | $175 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 66 | $157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $544 | $110,889148 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $126 | $85,90190 claims |
| PfizerPremarin | $22 | $10,23523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.
Other urogynecology and reconstructive pelvic surgery in Tampa
- Allison WymanTampa$69K
- Ryan HidalgoTampa$13K
- Lennox HoyteTampa$8K
- Nathan KowOrlando$116K
- Amir ShariatiCoconut Creek$106K
- Charbel SalamonOrlando$100K
- Nicole SzellLargo$54K
- Jose Lazaro WeissOviedo$28K
- Paul PettitJacksonville$27K
- Arash RahiCoconut Creek$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.